The Danish Competition Appeals Tribunal upholds the decision fining a pharmaceutical distributor for excessive pricing (CD Pharma)

Kasten, Tim

Previous article The Czech Supreme Court confirms that invoking trademark rights to prevent parallel imports can amount to an abuse of dominance (Fiskars / Mountfield) Next article The Hellenic Competition Authority fines a pharmaceutical company for reducing supplies of medicines to wholesalers (GlaxoSmithKline)

29 Nov 2018

The Danish Competition Appeals Tribunal upholds the decision fining a pharmaceutical distributor for excessive pricing (CD Pharma)

KEYWORDS

Reference

Danish Competition Appeals Tribunal, CD Pharma, Case No. KL-2-2018, Judgement, 29 November 2018 (Danish)

On 29 November 2018, the Danish Competition Appeals Tribunal upheld a 31 January 2018 decision of the Danish Competition Authority (“DCA”) finding that CD Pharma abused its dominant position on the Danish market by charging excessive prices for the sale of oxytocin, a hormone that acts as a neurotransmitter in the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Tim Kasten
Van Bael & Bellis (Brussels)

Belgium 191 contributions 64156 visits

Quotation

Tim Kasten, The Danish Competition Appeals Tribunal upholds the decision fining a pharmaceutical distributor for excessive pricing (CD Pharma), 29 November 2018, e-Competitions Parallel imports, Art. N° 88967

Visites 598